Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Johnson & Johnson shares gain as Q4 earnings and guidance beat

Published 24/01/2023, 12:01
Updated 24/01/2023, 12:01
© Reuters.

© Reuters.

By Investing.com Staff

Shares of Johnson & Johnson (NYSE:JNJ) rose in pre-open trading Tuesday after the pharmaceutical giant reported better-than-expected fourth quarter earnings results and earnings guidance.

Fourth quarter sales declined 4.4% to $23.7 billion on unfavorable foreign exchange and reduced COVID-19 vaccine sales. This was below the Wall Street consensus of $23.9B.

For the year, sales rose by 1.3% to $94.9B primarily driven by strong commercial execution partially offset by unfavorable foreign exchange.

On the bottom line, adjusted EPS rose by 10.3% to $2.35, beating the Wall Street consensus of $2.24.

"Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said CEO Joaquin Duato. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value."

Looking ahead, the company sees FY 2023 EPS growth of 3.5%, or $10.50. This is above the current Wall Street consensus of $10.33. The company sees 2023 adjusted operational sales growth of 4%, excluding COVID-19 vaccine sales.

Shares of JNJ last traded at $172.57, up 2.5%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.